SCHEMBL6014000

SCHEMBL6014000

COc1ccc(C[CH]c2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 1/20 0.55
KCNH2 Q12809 1/20 0.55
PTGS2 P35354 2/20 0.54
PTGS1 P23219 1/20 0.54
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
MAPT P10636 3/20 0.50
NFE2L2 Q16236 1/20 0.50
APP P05067 1/20 0.50
TLR9 Q9NR96 1/20 0.50
RAB9A P51151 1/20 0.50
ALDH1A1 P00352 5/20 0.49
LMNA P02545 3/20 0.49
POLB P06746 1/20 0.49
HTT P42858 1/20 0.48
NCOA1 Q15788 1/20 0.48
NCOA3 Q9Y6Q9 1/20 0.48
MEN1 O00255 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6567516 1.00 KCNJ1 (0.55) KCNJ1KCNH2PTGS2PTGS1MAOA
SCHEMBL1930129 0.83 ALDH1A1 (0.61) PTGS2NFE2L2ALDH1A1LMNACYP1A2
SCHEMBL7655222 0.83 ACHE (0.60) PTGS2MAOAMAOBMAPTNFE2L2
SCHEMBL322726 0.83 ACHE (0.60) PTGS2MAOAMAOBMAPTNFE2L2
SCHEMBL8021579 0.81 PTGS2 (0.63) PTGS2MAPTTLR9RAB9AALDH1A1
SCHEMBL9128800 0.81 PTGS2 (0.68) PTGS2MAPTTLR9RAB9AALDH1A1
SCHEMBL1005735 0.80 PTGS2 (0.78) PTGS2PTGS1MAOAMAOBMAPT
SCHEMBL14880486 0.80 PTGS2 (0.63) KCNJ1KCNH2PTGS2PTGS1MAOA
SCHEMBL1005734 0.80 PTGS2 (0.78) PTGS2PTGS1MAOAMAOBMAPT
SCHEMBL14880488 0.80 KCNJ1 (0.63) KCNJ1KCNH2MAPTAPPRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0072757-A1 Cephalosporin derivatives and their preparation RHONE-POULENC SANTE (FR) 1983-02-23 EP claimed
US-7045619-B2 2-(pyrazol-3-yl)carbapenem derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2006-05-16 US disclosed
US-20060078503-A1 1,4,7,10-Tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them PLATZEK JOHANNES 2006-04-13 US disclosed
EP-1432682-B1 PROCESS FOR THE PREPARATION OF REPAGLINIDE RANBAXY LAB LTD (IN) 2005-05-25 EP disclosed
EP-1404691-A2 METHOD FOR PRODUCING PERACYLATED 1-O-GLYCOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-07 EP disclosed
US-20030166923-A1 2-(pyrazol-3-yl)carbapenem derivatives SMITHKLINE BEECHAM P.L.C. 2003-09-04 US disclosed
WO-2003006474-A2 METHOD FOR PRODUCING PERACYLATED 1-O-GLYCOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-23 WO disclosed
US-20020147333-A1 2-(pyrazol-3-yl)carbapenem derivatives SMITHKLINE BEECHAM P.L.C. 2002-10-10 US disclosed
EP-0823911-A1 ESTERS OF CARBAPENEMS SMITHKLINE BEECHAM PLC (GB) 1998-02-18 EP disclosed
US-5612477-A 2-(pyrazol-3-yl)carbapenem derivatives SMITHKLINE BEECHAM P.L.C 1997-03-18 US disclosed
US-5606051-A 2-(pyrazol-3-yl)carbapenem derivatives SMITHKLINE BEECHAM P.L.C. (GB) 1997-02-25 US disclosed
WO-1996034869-A1 ESTERS OF CARBAPENEMS SMITHKLINE BEECHAM PLC (GB) 1996-11-07 WO disclosed
EP-0725783-A1 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 1996-08-14 EP disclosed
WO-1995011905-A1 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 1995-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060078503-A1 1,4,7,10-Tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them UGT2B17, CYP3A7, UGT2B7 KCNJ1 1856/4885KCNH2 1575/4885PTGS2 382/4885
US-20020147333-A1 2-(pyrazol-3-yl)carbapenem derivatives DPEP1, DHPS, JMJD6 KCNJ1 1743/4885KCNH2 1263/4885PTGS2 2675/4885
US-20030166923-A1 2-(pyrazol-3-yl)carbapenem derivatives DHPS, DPEP1, JMJD6 KCNJ1 1456/4885KCNH2 1102/4885PTGS2 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.